Key Takeaways AMRX trades at 1.69x sales versus 2.43x for its sub-industry and sector benchmarks.AMRX kept 2026 revenue guidance and raised adjusted EBITDA to $740M-$770M and EPS outlook.Rytary erosion is a 2026 overhang, while launches, margins and cash flow remain key catalysts.Amneal Pharmaceuticals (AMRX) is coming off a strong 12-month run, but the stock’s valuation still screens as discounted versus key benchmarks. That combination can keep investor attention high, especially when the operating story ...